和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
DOSING OF FIRST PATIENT OF NEXT-GEN ANTI-CTLA-4 ANTIBODY HBM4003 IN COMBINATION WITH PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) ANTIBODY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER ("NSCLC")

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about its latest business updates.

The board of directors of the Company (the "**Board**") is pleased to announce the dosing of the first patient of HBM4003 in patients with advanced NSCLC and other solid tumors in its open phase I clinical study. HBM4003 is a next-generation, fully human anti-CTLA-4 monoclonal heavy chain only antibody and this study tests its combined use with programmed cell death protein 1 (PD-1) antibody/chemotherapy. This study will evaluate the safety, tolerability, PK/PD and initial efficacy of HBM4003 in the treatment of solid tumors.

As disclosed in the Company's announcement on 26 February 2021, National Medical Products Administration (the "**NMPA**") of the People's Republic of China has granted approval of the Group's Investigational New Drug ("**IND**") application for the trial of HBM4003 in combination with programmed cell death protein 1 (PD-1) antibody/chemotherapy in patients with advanced NSCLC and other solid tumors. NMPA has also granted approval of the Group's IND application for the trial of HBM4003 in combination with programmed cell death protein 1 (PD-1) antibody in patients with advanced melanoma and other solid tumors. The phase I clinical trial is ongoing.

About HBM4003

HBM4003 is the fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from Harbour Mice®. HBM4003 shows enhanced antibody-dependent cell cytotoxicity (ADCC) killing activity and is extremely specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug.

Cautionary Statement: we cannot guarantee that we will be able to develop, or ultimately market, HBM4003 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 17 June 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.